Profile data is unavailable for this security.
About the company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).
- Revenue in USD (TTM)0.00
- Net income in USD-19.02m
- Incorporated2014
- Employees14.00
- LocationImmix Biopharma Inc11400 West Olympic Blvd., Suite 200LOS ANGELES 90064United StatesUSA
- Phone+1 (310) 651-8041
- Websitehttps://immixbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc | 16.45m | -14.11m | 34.32m | 14.00 | -- | 0.8375 | -- | 2.09 | -0.5507 | -0.5507 | 0.6871 | 1.56 | 0.3726 | -- | 6.53 | 1,174,929.00 | -31.95 | -58.31 | -36.01 | -65.94 | -- | -- | -85.75 | -137.92 | -- | -10.80 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Bright Green Corp | 0.00 | -9.92m | 36.11m | 5.00 | -- | 3.66 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Eyenovia Inc | 31.41k | -37.28m | 39.11m | 57.00 | -- | -- | -- | 1,245.19 | -0.7897 | -0.7897 | 0.0007 | -0.0425 | 0.0013 | -- | 0.0418 | 551.05 | -154.24 | -80.31 | -262.28 | -117.70 | -1,489.11 | -- | -118,693.60 | -680.95 | 0.267 | -40.92 | 1.20 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 39.81m | 317.00 | -- | 0.4734 | 29.66 | 0.3312 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Fortress Biotech Inc | 82.62m | -49.54m | 43.80m | 186.00 | -- | 2.43 | -- | 0.5302 | -3.71 | -3.71 | 6.05 | 0.7915 | 0.5063 | 2.36 | 6.07 | 444,215.10 | -65.90 | -52.50 | -113.69 | -99.46 | 68.77 | 63.17 | -130.17 | -236.94 | 1.24 | -13.40 | 1.26 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
| Aadi Bioscience Inc | 23.82m | -65.44m | 45.29m | 70.00 | -- | 0.5748 | -- | 1.90 | -2.43 | -2.43 | 0.8829 | 3.20 | 0.1884 | 0.6393 | 4.96 | 267,606.80 | -51.76 | -50.25 | -60.12 | -56.15 | 87.18 | -- | -274.77 | -473.97 | 3.92 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
| Earth Science Tech Inc | 20.30m | 1.98m | 48.24m | 32.00 | 24.43 | 15.24 | 22.49 | 2.38 | 0.0064 | 0.0064 | 0.0658 | 0.0103 | 5.40 | 36.44 | -- | 634,456.90 | 52.57 | -37.98 | 77.89 | -- | 69.40 | 63.87 | 9.74 | -15.48 | 1.24 | 3.57 | 0.0261 | -- | 24,526.37 | 73.03 | 322.25 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -19.02m | 49.69m | 14.00 | -- | 2.08 | -- | -- | -0.8411 | -0.8411 | 0.00 | 0.871 | 0.00 | -- | -- | 0.00 | -86.64 | -- | -100.82 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| Odonate Inc | 0.00 | -102.07m | 49.87m | 137.00 | -- | 1,839.01 | -- | -- | -13.59 | -13.59 | 0.00 | 9.27 | 0.00 | -- | -- | 0.00 | -66.98 | -58.36 | -83.00 | -65.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | -- | -- |
| Lexaria Bioscience Corp | 411.01k | -4.85m | 51.54m | 5.00 | -- | 5.09 | -- | 125.40 | -0.4455 | -0.4455 | 0.0408 | 0.6403 | 0.0539 | -- | 2.16 | 82,202.00 | -63.85 | -95.67 | -65.93 | -96.58 | 98.83 | 76.98 | -1,185.15 | -1,612.76 | -- | -64.96 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 57.53m | 134.00 | 4.86 | 0.2302 | 1.76 | 0.2234 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
| Qilian International Holding Group Ltd | 29.87m | -7.86m | 58.25m | 298.00 | -- | 1.33 | -- | 1.95 | -1.10 | -1.10 | 4.18 | 6.07 | 0.5237 | 3.73 | 25.96 | 100,236.40 | -14.43 | 2.71 | -17.01 | 3.86 | 2.92 | 11.66 | -27.56 | 2.72 | 6.06 | -0.7527 | 0.00 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
| SCYNEXIS Inc | 9.67m | -35.39m | 60.19m | 29.00 | -- | 0.9965 | -- | 6.23 | -0.735 | -0.735 | 0.2005 | 1.60 | 0.0736 | -- | 0.7011 | 333,344.80 | -26.95 | -30.02 | -31.99 | -36.35 | -55.82 | -- | -366.09 | -86.76 | -- | -- | 0.1747 | -- | 2,652.72 | 252.64 | 206.74 | -- | -- | -- |
| United-Guardian, Inc. | 12.31m | 3.25m | 66.80m | 25.00 | 20.58 | 5.51 | 19.94 | 5.43 | 0.7065 | 0.7065 | 2.68 | 2.64 | 0.9575 | 4.12 | 7.65 | 492,387.20 | 25.25 | 29.84 | 28.67 | 34.39 | 50.66 | 55.31 | 26.37 | 28.79 | 6.99 | -- | 0.00 | 97.37 | -14.28 | -4.14 | 0.4616 | -9.92 | 17.19 | -19.73 |
Data as of Sep 18 2024. Currency figures normalised to Immix Biopharma Inc's reporting currency: US Dollar USD
16.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 30 Jun 2024 | 1.41m | 5.12% |
| Bleichroeder LPas of 30 Jun 2024 | 850.00k | 3.10% |
| Cable Car Capital LLCas of 30 Jun 2024 | 796.10k | 2.90% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 598.54k | 2.18% |
| Lynwood Capital Management, Inc.as of 31 Mar 2024 | 405.00k | 1.48% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 154.69k | 0.56% |
| Geode Capital Management LLCas of 30 Jun 2024 | 142.13k | 0.52% |
| Next Edge Capital Corp.as of 30 Jun 2024 | 85.00k | 0.31% |
| Private Advisor Group LLCas of 30 Jun 2024 | 65.18k | 0.24% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 58.46k | 0.21% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
